Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis

Oku, Hiromasa; Shimizu, Tetsuji; Kawabata, Tomoji; Nagira, Morio; Hikita, Ichiro; Ueyama, Azumi; Matsushima, Shuuichi; Torii, Mikinori; Arimura, Akinori

doi:10.1016/j.ejphar.2008.06.046

Cited by 371 publications

(299 citation statements)

References 46 publications

Supporting

Mentioning

275

Contrasting

Unclassified

Order By: Relevance

“…The premise of this unbiased and disease-focused translational science approach is the hope that a translational gene panel will provide better preclinical information on the potential of novel therapeutics for IPF. Interestingly, this novel gene set only partially overlaps with well described markers reported in the literature (23,(59)(60)(61). To exemplify our translational approach, we used pirfenidone (Esbriet), which is the only currently approved drug for the treatment of IPF, to see how this novel translational gene set responds to drug treatment in the bleomycin-induced rat lung fibrosis model.…”

Section: Original Researchmentioning

confidence: 99%

A Novel Genomic Signature with Translational Significance for Human Idiopathic Pulmonary Fibrosis

Bauer

Tedrow²,

Bernard³

et al. 2015

Am J Respir Cell Mol Biol

155

View full text Add to dashboard Cite

show abstract

Section: Original Researchmentioning

confidence: 99%

A Novel Genomic Signature with Translational Significance for Human Idiopathic Pulmonary Fibrosis

Bauer

Tedrow²,

Bernard³

et al. 2015

Am J Respir Cell Mol Biol

155

View full text Add to dashboard Cite

show abstract

“…Pirfenidone reduced the production of transforming growth factor-β1 (TGF-β1), a profibrotic and pro-inflammatory cytokine, in the lungs of animal models of pulmonary fibrosis [22,23].…”

Section: Resultsmentioning

confidence: 99%

Reduction of Postoperative Adhesions after Laparoscopic Surgery for Endometriosis by Using a Novel Anti-Fibrotic Drug Pirfenidone: A Randomized Double Blind Study

El-Halwagy¹,

Al-Gergawy²,

Dawood³

et al. 2017

Gynecol Obstet

View full text Add to dashboard Cite

“…Relatively little pre-clinical data has been published on the in vitro or in vivo effects of either nintedanib or pirfenidone in fibrosing disease. Both drugs have, however, been shown to be effective in reducing bleomycin-induced fibrosis in rodents when dosed therapeutically and so provide a degree of validation for this model (Chaudhary et al, 2007;Oku et al, 2008;Kakugawa et al, 2004).…”

Section: Accepted M Manuscriptmentioning

confidence: 99%

Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy

Spagnolo¹,

Maher²,

Richeldi³

2015

Pharmacology & Therapeutics

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades our understanding of disease pathogenesis has substantially evolved and novel compounds have been developed consequent to the increasing knowledge of the mechanisms underlying disease pathobiology. The disease appears to be driven - following chronic injury - by abnormal/dysfunctional alveolar epithelial cells that promote fibroblast recruitment and proliferation, resulting in scarring of the lung and irreversible loss of function. With very few exceptions, clinical trials evaluating novel potential therapies have provided disappointing results. More recently, pirfenidone and nintedanib, two compounds with pleiotropic mechanisms of action, have proven effective in slowing functional decline and disease progression in IPF patients with mild to moderate functional impairment, highlighting the importance of timely diagnosis and administration of treatment in early stages of disease. However, due to the complexity and uncertainties intrinsic to IPF, it is essential that each therapeutic strategy be tailored to the individual patient, after evaluation of potential benefits and risks. This article provides an overview of the most recent clinical trials in IPF and discusses how their results are going to change the clinical and clinical research landscape in IPF. A number of agents with high potential are currently being tested and many more are ready for clinical trials. Their completion is critical for achieving the ultimate goal of curing patients with IPF

show abstract

Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis

Cited by 371 publications

References 46 publications

A Novel Genomic Signature with Translational Significance for Human Idiopathic Pulmonary Fibrosis

A Novel Genomic Signature with Translational Significance for Human Idiopathic Pulmonary Fibrosis

Reduction of Postoperative Adhesions after Laparoscopic Surgery for Endometriosis by Using a Novel Anti-Fibrotic Drug Pirfenidone: A Randomized Double Blind Study

Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy

Contact Info

Product

Resources

About